GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.